Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
Conference Coverage
ASH: Carfilzomib doubles progression free survival in head-to-head trial with bortezomib
Publish date:
December 5, 2015
FROM ASH 2015
References
koakes@frontlinemedcom.com
On Twitter
@karioakes
Pages
« first
1
2
Recommended Reading
Ixazomib approved for multiple myeloma combo treatment
MDedge Hematology and Oncology
Elotuzumab approved for multiple myeloma
MDedge Hematology and Oncology
Multiple myeloma advances will be a hot topic at ASH
MDedge Hematology and Oncology
Bone can reactivate dormant MM cells, study suggests
MDedge Hematology and Oncology
FDA approves elotuzumab for MM
MDedge Hematology and Oncology
Prognostic test for MM granted CE-IVD mark
MDedge Hematology and Oncology
Template can help guide care for cancer survivors
MDedge Hematology and Oncology
EC approves carfilzomib for relapsed MM
MDedge Hematology and Oncology
FDA approves ixazomib for MM
MDedge Hematology and Oncology
Model enables screening of MM drugs
MDedge Hematology and Oncology
Multiple Myeloma
Lymphoma & Plasma Cell Disorders
All Specialties
